Monday, May 6, 2024
Facebook Linkedin Twitter
HomeTagsWP1122

WP1122

Biotechnology

Moleculin Receives FDA Orphan Drug Designation of WP1122

PR Newswire -
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced that the...
Biotechnology

Moleculin Announces Completion of Third SAD Cohort in Phase 1a Clinical Trial of WP1122

PR Newswire -
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported preliminary results...
Biotechnology

Moleculin Announces Completion of Second Single Ascending Dose Cohort in Phase 1a Clinical Trial

PR Newswire -
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported preliminary results...
Biotechnology

Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

PR Newswire -
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported preliminary results...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us